共 50 条
- [31] Safety and Efficacy of Ruxolitinib Retreatment after Treatment Interruption in Patients Enrolled in an Open-Label, Multicenter, Expanded-Access Study in MyelofibrosisBLOOD, 2014, 124 (21)Gupta, VikasTavares, Renato S.Griesshammer, MartinFoltz, Lynda M.Raanani, PiaGiraldo, PilarAl-Ali, Haifa KathrinMartino, BrunoTannir, BayaneRonco, Julian PerezGhosh, JagannathVannucchi, Alessandro M.
- [32] Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity ConditioningBLOOD, 2019, 134Ali, HarisSnyder, DavidStiller, TracySynold, TimothyMokhtari, SaloomehPalmer, JoycelynneSalhotra, AmandeepPullarkat, Vinod A.Cai, Ji-lianForman, Stephen J.Mei, MatthewNakamura, Ryotaro
- [33] A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosisHAEMATOLOGICA, 2017, 102 (01) : 94 - 102Gupta, VikasMesa, Ruben A.Deininger, Michael W. N.Rivera, Candido E.Sirhan, ShireenBrachmann, Carrie BakerCollins, HelenKawashima, JunXin, YanVerstovsek, Srdan
- [34] A Phase 3, Open-Label, Randomized Study Evaluating the Efficacy and Safety of Navitoclax Plus Ruxolitinib Versus Best Available Therapy in Patients with Relapsed/Refractory Myelofibrosis (TRANSFORM-2)BLOOD, 2020, 136Dilley, KimberleyHarb, JasonJalaluddin, MuhammadHutti, Jessica E.Potluri, Jalaja
- [35] Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 studyLeukemia, 2021, 35 : 3626 - 3626Francisco CervantesDavid M. RossAtanas RadinoffFrancesca PalandriAlexandr MyasnikovAlessandro M. VannucchiPierre ZacheeHeinz GisslingerNorio KomatsuLynda FoltzFrancesco MannelliFrancesco PassamontiGeralyn GilottiIslam SadekRanjan TiwariEvren ZorHaifa Kathrin Al-Ali
- [36] Ruxolitinib cream for discoid lupus erythematosus: An open-label pilot study of ten patientsJOURNAL OF INVESTIGATIVE DERMATOLOGY, 2024, 144 (08) : S163 - S163Bender, A. M.Kaur, J.Babkowski, N.Richardson, C. T.
- [37] An Open-Label, Phase II Study Of The JAK1 Inhibitor INCB039110 In Patients With MyelofibrosisBLOOD, 2013, 122 (21)Mascarenhas, JohnTalpaz, MosheGupta, VikasSavona, MichaelCoughlin, PaulWinton, ElliottHunter, DeborahMookerjee, BijoyeshLeopold, LanceClark, JasonO'Neill, PeterHoffman, RonaldVerstovsek, Srdan
- [38] HARMONY: An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis (MF)BLOOD, 2014, 124 (21)Durrant, SimonKoren-Michowitz, MayaLavie, DavidMartinez-Lopez, JoaquinVannucchi, Alessandro M.Passamonti, FrancescoStalbovskaya, ViktoriyaAtienza, EdricIommazzo, DanaGopalakrishna, PrashanthGisslinger, Heinz
- [39] Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre studyLANCET HAEMATOLOGY, 2017, 4 (07): : E317 - E324Harrison, Claire N.Schaap, NicolaasVannucchi, Alessandro M.Kiladjian, Jean-JacquesTiu, Ramon V.Zachee, PierreJourdan, EricWinton, ElliottSilver, Richard T.Schouten, Harry C.Passamonti, FrancescoZweegman, SonjaTalpaz, MosheLager, JoanneShun, ZhenmingMesa, Ruben A.
- [40] Pharmacokinetics of eflapegrastim in a phase 2 open-label dose-ranging study in breast cancer patients receiving TC regimenCANCER RESEARCH, 2017, 77Vacirca, J. L.Papai, Z.Horvath, Z.Makharadze, R.Reddy, G.Song, T.Koli, P.Schwartzberg, L. S.